Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Apr 1;6(1):141.
doi: 10.1038/s41392-021-00557-9.

Therapeutic utility of Lung-MAP: ushering into an era of genomic and biomarker-driven clinical trials

Chenyue Zhang  1 , Haiyong Wang  2
Affiliations
Comment

Therapeutic utility of Lung-MAP: ushering into an era of genomic and biomarker-driven clinical trials

Chenyue Zhang et al. Signal Transduct Target Ther. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Clinical trial design flow chart to guide individualized treatment. a The schema demonstrates the protocol of the umbrella study. Eligible patients of a specific cancer type are assigned to sub-studies based on their biomarkers or to a “nonmatch” sub-study if the patient does not qualify for the biomarker-specific sub-studies. b Patients are assigned to individualized treatments according to their biomarkers. Treatment continues within each sub-study until tumor progression has been detected. Patients would be reassigned based on biomarker screening again. This is a repeated process. c The schema demonstrates the protocol of the basket study. Patients with different cancer types are assigned to sub-studies based on their biomarkers. They would undergo a targeted therapy directed against a specific genetic mutation even in different cancer types
See this image and copyright information in PMC

Comment on

References

    1. Redman MW, et al. Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol. Lancet Oncol. 2020;21:1589–1601. doi: 10.1016/S1470-2045(20)30475-7. - DOI - PMC - PubMed
    1. Jiang T, et al. Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma. J. Hematol. Oncol. 2019;12:75. doi: 10.1186/s13045-019-0762-1. - DOI - PMC - PubMed
    1. Hamzehzadeh L, et al. The versatile role of curcumin in cancer prevention and treatment: a focus on PI3K/AKT pathway. J. Cell. Physiol. 2018;233:6530–6537. doi: 10.1002/jcp.26620. - DOI - PubMed
    1. Goel S, DeCristo MJ, McAllister SS, Zhao JJ. CDK4/6 inhibition in cancer: beyond cell cycle arrest. Trends Cell Biol. 2018;28:911–925. doi: 10.1016/j.tcb.2018.07.002. - DOI - PMC - PubMed
    1. Sootome H, et al. Futibatinib is a novel irreversible FGFR 1-4 inhibitor that shows selective antitumor activity against FGFR-deregulated tumors. Cancer Res. 2020;80:4986–4997. doi: 10.1158/0008-5472.CAN-19-2568. - DOI - PubMed

Publication types